ALBT

Avalon GloboCare Corp. together with its subsidiaries owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics precision diagnostics and clinical laboratory services. Its leading candidates are AVA-001 an anti-CD19 CAR-T which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT) including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation transposon-based multi-target CAR-T CAR-NK and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide LLC to engage in co-development and commercialization of a series of clinical-grade exosome-based cosmeceutical and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold New Jersey.